One stock that has been lighting it up thus far in 2019 is Generex Biotechnology Corporation (OTCMKTS:GNBT). Shares of the stock have as much as tripled since late December on a host of catalysts, the latest of which is its announcement that Olaregen Therapeutix Inc, a subsidiary of Generex Biotechnology, will launch three doses of FDA 510K-Cleared Excellagen, the company’s wound conforming gel matrix that is designated as a Cellular & Tissue-Based Product or CTP for wound healing.
According to the release, “The 0.5 cc and a 0.8 cc syringes will be utilized to treat smaller wounds such as diabetic foot ulcers, venous stasis ulcers, and pressure ulcers, and in patients who have undergone MOHs surgery for removal of cancerous tissue. The 3 cc syringe has been developed for larger wounds that are most frequently seen in emergency departments, operating rooms, and surgical suites. Excellagen has a designated reimbursement code in the Healthcare Common Procedure Coding System, with a unique Q Code designation 4149 referred to as a skin substitute.”
Generex Biotechnology Corporation (OTCMKTS:GNBT) bills itself as a company that, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States.
It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices.
The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.
According to company materials, “Generex Biotechnology Corp. (GNBT) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our company creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. The company goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.”
Find out when $GNBT reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, GNBT just announced that Olaregen Therapeutix Inc, a subsidiary of Generex Biotechnology, will launch three doses of FDA 510K-Cleared Excellagen, the company’s wound conforming gel matrix that is designated as a Cellular & Tissue-Based Product or CTP for wound healing.
The chart shows approaching 120% tacked on to share pricing for the stock in the past month. Moreover, the name has seen a growing influx of trading interest, with the stock’s recent average trading volume running 88% over the long run average.
“We’ve heard time and again about the issue of waste, or the need for multiple applications per a single procedure because the existing products don’t necessarily accommodate the size of the wound. This is not only time consuming for the doctor but is cost inefficient,” said Anthony J. Dolisi, Chief Executive Officer of Olaregen.
“As part of our commitment to our customers, we listen carefully to their needs. After a thorough analysis of the market, and through discussions with physicians, we determined that Olaregen will launch Excellagen with multiple dosage options that offer clinical flexibility and cost savings with improved clinical outcomes.”
Now commanding a market cap of $159.77M, GNBT has a bankroll ($2.4M) of cash on the books, which stands against about $42.9M in total current liabilities. One should also note that debt has been growing over recent quarters. GNBT is pulling in trailing 12-month revenues of $2.4M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 77408.9%. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $GNBT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $GNBT, either long or short, and we have not been compensated for this article.